Analysis
Delix Therapeutics, a Massachusetts-based clinical-stage neuroscience company, closed an oversubscribed $100 million Series C co-led by Johnson & Johnson Innovation -- JJDC and SV Health Investors' Dementia Discovery Fund to advance its lead drug candidate, zalsupindole, into Phase II trials for major depressive disorder, Pulse2 reported.
What Delix Therapeutics does
Delix develops neuroplasticity-promoting medicines, led by CEO Mark Rus and co-founded by Nick Haft, a partner at OMX Ventures. Its lead candidate, zalsupindole (also known as DLX001), is an orally administered drug designed to promote structural and functional changes in neural connections without the hallucinogenic effects of classic psychedelics. The company expects to begin a placebo-controlled Phase IIb proof-of-concept trial in recurrent major depressive disorder during the first half of 2027.
Delix's funding history -- how much has Delix raised
Delix raised a $70 million Series A in September 2021, led by ARTIS Ventures, RA Capital Management and founding investor OMX Ventures, with additional participation from Apeiron, Bail Capital and Casa Verde Capital, BioSpace reported at the time. That round, like many biotech Series A deals, brought together generalist life-sciences funds and a founding investor willing to keep writing checks as the company advanced toward clinical proof-of-concept -- the stage this new $100 million Series C is designed to fund. The new round adds to that total, and comes as an oversubscribed round -- meaning investor demand exceeded the amount Delix set out to raise, typically a signal that existing backers see a clearer regulatory and clinical path than when they first invested.
“The company expects to begin a placebo-controlled Phase IIb proof-of-concept trial in recurrent major depressive disorder during the first half of 2027.”
Who invested in Delix's Series C
The round was co-led by Johnson & Johnson Innovation -- JJDC and SV Health Investors' Dementia Discovery Fund. Pulse2 named existing backers RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital as participating -- RA Capital, Artis Ventures, OMX Ventures and Bail Capital also backed the 2021 Series A, while the round disclosures do not specify when UC Investments and Dolby Family Ventures first invested -- joined by new investors Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital and YK Bioventures. JJDC's participation is notable: large pharma corporate venture arms typically co-lead rounds in therapeutics they view as future licensing, partnership or acquisition candidates, a dynamic also tracked across the deals in our venture funding coverage. Having both a dementia-focused fund and a pharma innovation arm as co-leads also signals that investors see zalsupindole's neuroplasticity mechanism as relevant beyond depression alone, into other conditions tied to neural connectivity.
Neuroplasticity drug market and competitors
Delix's raise follows a string of large rounds in neuroplasticity and neuropsychiatric drug development. Seaport Therapeutics closed an oversubscribed $225 million Series B in October 2024, led by General Atlantic, to advance its own novel neuropsychiatric medicines -- more than twice the size of Delix's new round, and a sign of how much capital has flowed into drugs that target brain chemistry without classic psychedelic side effects. Both companies are racing to prove that neuroplasticity-focused chemistry can treat depression and related disorders with a cleaner regulatory and safety profile than psilocybin- or ketamine-derived treatments. Delix's raise is also the latest in a run of large biotech venture rounds Pulse has tracked this month, including T-Therapeutics' $133 million Series B for cancer and autoimmune TCR therapies -- a reminder that biotech megarounds are competing for the same generalist and corporate-venture capital as AI and defense-tech deals.
What to watch next
The real test comes in the first half of 2027, when Delix's Phase IIb proof-of-concept trial reads out in recurrent major depressive disorder. A positive signal would validate the neuroplasticity-without-hallucination thesis that drew JJDC and SV Health's dementia-focused fund into the round; a miss would leave Delix needing another large raise before any pharma partner commits further.
